miércoles, 1 de noviembre de 2023

FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases

https://www.fda.gov/news-events/press-announcements/fda-approves-interchangeable-biosimilar-multiple-inflammatory-diseases?utm_medium=email&utm_source=govdelivery U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases.

No hay comentarios: